CLOs on the Move

ReCode Therapeutics

www.recodetx.com

 
ReCode Therapeutics is a biopharmaceutical company developing precision medicines for pulmonary diseases with significant unmet medical need.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

BioExx Specialty Proteins

BioExx Specialty Proteins Ltd. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Ichnos Sciences

The spirit of a start-up. The experience of an established biotech. Ichnos (`īk-nōz) Sciences—a name taken from an ancient Greek word for “footprint”—is shifting how the world thinks about innovation in medicine. With a new approach to the research, discovery, and development of breakthrough therapies in oncology, autoimmune disease and pain management, we`re forging a new path forward. We aim to treat disease holistically, seeking to provide curative therapies that extend human life and improve quality of life. Science SHIFTED…from now on. Headquartered in the NYC metro area, with additional teams in Switzerland and India, ours is a mission rooted in purpose and aimed at progress. Ichnos Sciences is fast-paced, forward-looking and visionary—a company where science, creativity, and a diversity of ideas thrive. We move quickly and nimbly, working together, challenging and supporting one another and ourselves to go further, look deeper, take scientific risks, shift perspectives, and drive forward the scientific advances that will leave an imprint on the world around us. At Ichnos Sciences, we dare to imagine a world where cure is possible. And we invite you to join us. Because cure is possible.

Stemline Therapeutics

Stemline Therapeutics is a clinical stage biopharmaceutical company developing oncology compounds that target cancer stem cells.

Zacharon

Zacharon is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ambagon Therapeutics

Ambagon’s approach selectively augments the endogenous tumor suppression activity of 14-3-3 proteins bound to transcription factors and oncoproteins that have proven challenging to modulate with conventional approaches. Ambagon’s platform approach will...